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Abstract
Objectives
To estimate hepatitis C virus (HCV) viremic rate, defined as the proportion of HCV chroni-
cally infected individuals out of all ever infected individuals, in the Middle East and North
Africa (MENA).
Methods
Sources of data were systematically-gathered and standardized databases of the MENA
HCV Epidemiology Synthesis Project. Meta-analyses were conducted using DerSimonian-
Laird random-effects models to determine pooled HCV viremic rate by risk population or
subpopulation, country/subregion, sex, and study sampling method. Random-effects meta-
regressions were conducted to identify predictors of higher viremic rate.
Results
Analyses were conducted on 178 measures for HCV viremic rate among 19,593 HCV anti-
body positive individuals. In the MENA region, the overall pooled mean viremic rate was
67.6% (95% CI: 64.9–70.3%). Across risk populations, the pooled mean rate ranged
between 57.4% (95% CI: 49.4–65.2%) in people who inject drugs, and 75.5% (95% CI:
61.0–87.6%) in populations with liver-related conditions. Across countries/subregions, the
pooled mean rate ranged between 62.1% (95% CI: 50.0–72.7%) and 70.4% (95% CI: 65.5–
75.1%). Similar pooled estimates were further observed by risk subpopulation, sex, and
sampling method. None of the hypothesized population-level predictors of higher viremic
rate were statistically significant.
Conclusions
Two-thirds of HCV antibody positive individuals in MENA are chronically infected. Though
there is extensive variation in study-specific measures of HCV viremic rate, pooled mean
estimates are similar regardless of risk population or subpopulation, country/subregion,
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HCV antibody prevalence in the background population, or sex. HCV viremic rate is a useful
indicator to track the progress in (and coverage of) HCV treatment programs towards the
set target of HCV elimination by 2030.
Introduction
Viral hepatitis is ranked as the 7th leading cause of mortality worldwide [1], with nearly half of
this mortality attributed to hepatitis C virus (HCV) [1]. Despite its global burden, the Middle
East and North Africa (MENA) remains the most affected region [2, 3]. With the advent of
direct-acting antivirals (DAAs) to treat and cure HCV infection [4], a global target was set to
eliminate HCV infection by 2030 [5, 6].
A key feature of HCV natural history is that not all infected persons develop chronic infec-
tion [7–9]. While infected persons pass through a stage of acute infection for few months, and
develop antibodies against HCV infection, a proportion of them spontaneously clear the infec-
tion and becomes HCV antibody (Ab) positive but HCV ribonucleic acid (RNA) negative [7–
9]. The remainder of infected persons become chronic carriers of the infection and persist as
HCV Ab positive and RNA positive [7–9]. For a given population, the proportion of chroni-
cally infected individuals (HCV Ab positive and RNA positive), out of all ever infected individ-
uals (HCV Ab positive regardless of RNA status), defines the HCV viremic rate for this
population [10].
Assessing and understanding the HCV viremic rate is critical for biological, epidemiologi-
cal, and public health consequences. The HCV viremic rate provides a measure of HCV spon-
taneous clearance rate and its determinants, and how this rate may vary by population [11].
The HCV viremic rate furnishes also a direct measure of the likelihood that a member of a spe-
cific population is chronically infected, as well as an indirect measure of the risk of HCV rein-
fection in this population [11]. It is further essential for estimations of the number of HCV
chronic carriers in different populations and countries, and consequences for resource alloca-
tion and development of screening and treatment programs. The HCV viremic rate will also
play an increasingly important role in assessing and monitoring the progress in (and coverage
of) HCV treatment programs in different populations, as we forge ahead towards HCV elimi-
nation by 2030.
The HCV viremic rate has been assessed through numerous studies in different populations
globally, but its measures show extensive variability across studies [12–21]. The HCV clearance
rate, which is strongly linked to HCV viremic rate [11], has been also assessed in multiple pro-
spective cohort studies [7, 22–24], but its measures also show wide variation across studies
[11]. To our knowledge, no study have yet been conducted to provide an overall pooled esti-
mate and subgroup pooled estimates for the HCV viremic rate that factor the wide diversity of
studies for this measure. No study has also investigated the sources of heterogeneity in avail-
able HCV viremic rate measures.
Against this background, we aimed in the present study to provide pooled estimates for the
HCV viremic rate, overall and for different risk populations and different countries of the
MENA region. We also aimed to investigate the sources of heterogeneity in available measures
in MENA. These quantitative assessments were based on a comprehensive and standardized
database of systematically gathered HCV viremic rate data.
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This study was conducted as part of the MENA HCV Epidemiology Synthesis Project, an
ongoing effort to characterize HCV epidemiology and inform public health research, resource
allocation, policy, and programing priorities in MENA [11–21, 25, 26].
Methodology
Data sources
We retrieved studies reporting HCV RNA prevalence measures strictly among HCV Ab positive
individuals from the MENA HCV Epidemiology Synthesis Project databases. These databases
consist of 2,543 studies reporting HCV Ab prevalence among 52,598,736 participants, 47 stud-
ies reporting HCV Ab incidence among 29,600 participants, and 338 studies reporting HCV
genotypes among 82,257 participants. The retrieved HCV RNA prevalence measures were
nearly always extracted from studies whose main outcome measure was HCV Ab prevalence in
some specific population. HCV RNA prevalence was a secondary outcome of these studies.
The HCV Synthesis Project databases were compiled through systematic reviews of the lit-
erature [12–17, 19–21] that were informed by the Cochrane Collaboration handbook [27], and
reported as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines [28]. The literature searches were conducted using broad search criteria
with no language or year restrictions (S1 and S2 Boxes), and were based on international data-
bases (PubMed and Embase), regional databases, national databases, and the MENA HIV/
AIDS Epidemiology Synthesis Project database [29, 30]. Separate searches were also conducted
for the non-indexed literature consisting of public health reports and routine data reporting.
The flowcharts summarizing the searches can be found in the previous publications [12–17,
19–21]. The PRISMA checklist for the present study can be found in S1 Fig.
The definition of MENA for this project consisted of 24 countries including: Afghanistan,
Algeria, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania,
Morocco, Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, the
United Arab Emirates (UAE), and Yemen.
Study selection and classification
All studies reporting a measure of HCV viremic rate were included, provided the sample size
was10. The HCV viremic rate was defined as the proportion of HCV Ab positive and RNA
positive individuals out of all ever infected (i.e. HCV Ab positive) individuals in the sample.
The overall sample size was replaced by stratified measures whenever this was possible while
maintaining a subsample size10. The viremic rate measures were classified based on the per-
ceived risk of HCV exposure, as informed by existing classifications [2, 12–17, 19–21], as
follows:
1. General populations: populations at a low risk of being exposed to HCV infection such as
blood donors, healthy adults, healthy children, and pregnant women, among others. Those
referred to in included studies as “general populations” were labeled as other general popula-
tions to avoid confusion with the name of this category.
2. Populations at intermediate risk: populations at an intermediate risk of being exposed to
HCV infection such as health care workers, diabetics, and prisoners, among others).
3. Populations at high risk of healthcare-related exposures: populations at a high risk of being
exposed to HCV infection due to a medical condition that requires frequent injections or
blood transfusions such as hemodialysis, thalassemia, and hemophilia patients, among
others.
HCV viremic rate in the Middle East and North Africa
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4. People who inject drugs (PWID) who are at a high risk of being exposed to HCV infection
due to sharing of needles or syringes.
5. Populations with liver-related conditions: populations suffering from liver-related medical
conditions that could be linked (or attributed) to HCV infection, such as viral hepatitis,
hepatocellular carcinoma, and liver cirrhosis patients, among others.
6. Special clinical populations: populations with an undetermined risk of HCV exposure such
as patients with malignancies, rheumatology disorders, and autoimmune diseases, among
others.
Quantitative analysis
Meta-analyses. We conducted meta-analyses to estimate the pooled mean HCV viremic
rate for the different risk populations. The methods were adapted from earlier meta-analyses
[12–21, 26]. We used DerSimonian-Laird random-effects models with inverse variance
weighting whenever we had3 measures to be pooled [31]. The Freeman-Tukey type arcsine
square-root transformation was used to stabilize the variance of the proportion measures [32].
Heterogeneity in effect size between studies was assessed using the Cochran’s Q test; a p-value
<0.1 was considered significant [33, 34]. The I2 was used to assess the between-study variation
associated with differences in effect size [33]. The prediction interval was calculated to identify
the range where the true effect around the mean falls [33, 35].
Since we did not have sufficient number of studies to do a separate meta-analysis for each
individual MENA country, we conducted meta-analyses by country or relevant subregional
grouping (Afghanistan and Pakistan, Egypt, Fertile Crescent, Gulf, Iran, and Maghreb). The
Fertile Crescent included Iraq, Jordan, Lebanon, Palestine, and Syria. The Gulf included
Kuwait, Oman, and Saudi Arabia. The Maghreb included Algeria, Libya, Morocco, and Tuni-
sia. This country/subregion classification included all MENA countries for which data on
HCV viremic rate were available.
We further conducted meta-analyses for specific subpopulations among the general popula-
tion (blood donors, children, pregnant women/antenatal care attendees, and other general
populations), and specific subpopulations among the populations at high risk of healthcare-
related exposures (hemophilia patients, hemodialysis patients, and thalassemia patients). We
also conducted meta-analyses by sex (women only, men only, and mixed-sex), and by sam-
pling method of the original study (convenience sampling, national population-based and
probability-based sampling, and other probability-based sampling).
The meta-analyses were conducted using R studio version 3.3.2 [36] using the package
meta [37].
Meta-regressions and sources of heterogeneity. We conducted univariable and multi-
variable random-effects meta-regressions to identify the predictors of higher HCV viremic
rate and sources of between-study heterogeneity. The following independent variables were
specified a priori because of epidemiological relevance: risk population, country or subregion,
sex, age, HCV Ab prevalence of the sampled population, year of data collection, sample size,
and sampling method. Variables with a p-value <0.1 in the univariable analyses were eligible
for inclusion in the final multivariable model. Variables with a p-value<0.05 in the univariable
models or the final multivariable model were considered statistically significant.
Risk population, country/subregion, and sex variables were categorized as described in the
above sections. Age was categorized as children and adults. HCV Ab prevalence variable was
coded as a categorical variable with four prevalence ranges: 1–10%, 10–30%, 30–50%, and
>50%. The year of data collection variable was coded as a categorical variable with two date
HCV viremic rate in the Middle East and North Africa
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ranges: before 2000 and 2000 and thereafter. The sample size variable was categorized as50
and<50. The sampling method variable was categorized as probability-based sampling and
non-probability-based sampling.
For the year of data collection variable, we imputed the missing observations using the
median of the results of the subtraction of the year of data collection from the year of publica-
tion. A sensitivity analysis using the imputed and the non-imputed observations revealed no
impact on the statistical significance of the variable.
The meta-regressions were conducted using Stata/SE version 13 [38] using the package
metareg [39].
Results
Scope of evidence
We identified 178 measures for HCV viremic rate among 19,593 HCV Ab positive individuals
(Table 1). These measures included 81 in general populations, 20 in populations at intermedi-
ate risk, 51 in populations at high risk of healthcare-related exposures, five in PWID, eight in
populations with liver-related conditions, and 12 in special clinical populations. One study
was considered as “mixed” since the sample included a mix of general populations and an
intermediate risk population [40].
There were data on HCV viremic rate in 16 out of the 24 MENA countries (Table 1). Egypt
contributed the largest number of data points (n = 89), and the majority of these were from
studies in general populations.
HCV viremic rate
HCV viremic rate varied across and within the risk populations with a broad range of 9–100%
and a median of 68.8% (Table 2). The overall pooled mean HCV viremic rate (across all data
points) was 67.6% (95% confidence interval (CI): 64.9–70.3%).
Across the risk populations (Table 2), the pooled mean HCV viremic rate was lowest at
57.4% (95% CI: 49.4–65.2%) in PWID, followed by 66.9% (95% CI: 62.6–71.1%) in the general
populations, 67.1% (95% CI: 58.6–75.2%) in the populations at intermediate risk, 67.4% (95%
CI: 56.7–77.3%) in the special clinical populations, 68.5% (95% CI: 63.5–73.3%) in the popula-
tions at high risk healthcare-related exposures, and 75.5% (95% CI: 61.0–87.6%) in populations
with liver-related conditions.
Across countries or subregions (Table 3), the pooled mean HCV viremic rate was lowest at
62.1% (95% CI: 50.0–72.7%) in the Fertile Crescent, followed by 65.9% (95% CI: 55.3–75.9%)
in the Gulf, 67.0% (95% CI: 63.1–70.8%) in Egypt, 68.6% (95% CI: 63.2–73.8%) in Iran, 70.4%
(95% CI: 57.4–82.0%) in Afghanistan and Pakistan, and 70.4% (95% CI: 65.5–75.1%) in the
Maghreb.
Among the general populations (Table 4), the pooled mean HCV viremic rate was lowest
among children (54.0%, 95% CI: 37.6–70.0%), and highest among blood donors (76.3%, 95%
CI: 68.6–84.0%). Among populations at high risk of healthcare-related exposures, the pooled
mean HCV viremic rate was lowest among hemodialysis patients (66.5%, 95% CI: 59.9–
73.2%), and highest among hemophilia patients (73.6%, 95% CI: 63.9–82.3%)
By sex (Table 4), the pooled mean HCV viremic rate was 65.4% (95% CI: 60.1–70.6%)
among females, 67.4% (95% CI: 58.1–76.0%) among males, and 68.2% (95% CI: 64.9–71.3%)
among the mixed-sex samples.
By sampling method (Table 4), the pooled mean HCV viremic rate was 58.7% (95% CI:
49.4–67.6%) for studies using probability-based sampling but not at the national level, 68.7%
HCV viremic rate in the Middle East and North Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0187177 October 31, 2017 5 / 22
Table 1. Studies reporting hepatitis C virus (HCV) viremic rate stratified by risk population across countries of the Middle East and North Africa.
Country First author, year of publication Years of data collection Population description Number of HCV Ab positive individuals tested for RNA HCV viremic rate (%)
General populations (n = 81)
Egypt Abdel-Aziz, 2000 [46] 1997 Participants in a population-based survey 973 65.5
AbdulQawi, 2011 [47] 2003–08 Pregnant women/ANC attendees 105 79.0
Agha, 1998 [48] 1996–97 Pregnant women/ANC attendees 67 26.9
Aguilar, 2008 [49] - General population 40 67.5
Aguilar, 2008 [49] - General population 33 72.0
Arafa, 2005 [50] 2002–03 Participants in a population-based survey 456 59.9
Barakat, 2011 [51] 2005 Children 29 75.9
Cowgill, 2004 [52] 1999–03 General population 80 65.0
Darwish, 1995 [53] - Participants in a population-based survey 25 76.0
Derbala, 2014 [54] 2008–10 General population 315 100
El-Kamary, 2015 [55] 2012–13 Pregnant women/ANC attendees 52 58.0
El-Karaksy, 2010 [56] 2006–07 Children 15 33.3
El-Sadawy, 2004 [57] - Participants in a population-based survey 367 29.7
El-Sherbini, 2003 [58] 1994 Children 17 41.0
El-Zanaty, 2008 [41] 2008 15–19 years age group females in a national-based survey 178 67.8
El-Zanaty, 2008 [41] 2008 20–24 years age group females in a national-based survey 153 66.9
El-Zanaty, 2008 [41] 2008 25–29 years age group females in a national-based survey 94 62.9
El-Zanaty, 2008 [41] 2008 30–34 years age group females in a national-based survey 134 70.2
El-Zanaty, 2008 [41] 2008 35–39 years age group females in a national-based survey 129 69.3
El-Zanaty, 2008 [41] 2008 40–44 years age group females in a national-based survey 122 65.2
El-Zanaty, 2008 [41] 2008 45–49 years age group females in a national-based survey 109 60.0
El-Zanaty, 2008 [41] 2008 50–54 years age group females in a national-based survey 85 70.4
El-Zanaty, 2008 [41] 2008 55–59 years age group females in a national-based survey 107 68.8
El-Zanaty, 2008 [41] 2008 10–14 years age group males in a national-based survey 68 76.7
El-Zanaty, 2008 [41] 2008 20–24 years age group males in a national-based survey 65 62.6
El-Zanaty, 2008 [41] 2008 25–29 years age group males in a national-based survey 62 73.8
El-Zanaty, 2008 [41] 2008 30–34 years age group males in a national-based survey 59 53.6
El-Zanaty, 2008 [41] 2008 35–39 years age group males in a national-based survey 54 66.2
El-Zanaty, 2008 [41] 2008 40–44 years age group males in a national-based survey 50 61.1
El-Zanaty, 2008 [41] 2008 45–49 years age group males in a national-based survey 42 65.0
El-Zanaty, 2008 [41] 2008 50–54 years age group males in a national-based survey 32 74.6
El-Zanaty, 2008 [41] 2008 55–59 years age group males in a national-based survey 28 71.1
MoHP, 2015 [42] 2015 1–14 years age group females in a national-based survey 183 75.0
MoHP, 2015 [42] 2015 15–19 years age group females in a national-based survey 164 66.5
MoHP, 2015 [42] 2015 20–24 years age group females in a national-based survey 154 66.4
MoHP, 2015 [42] 2015 25–29 years age group females in a national-based survey 61 81.1
MoHP, 2015 [42] 2015 30–34 years age group females in a national-based survey 142 63.7
MoHP, 2015 [42] 2015 35–39 years age group females in a national-based survey 106 69.5
MoHP, 2015 [42] 2015 40–44 years age group females in a national-based survey 102 69.8
MoHP, 2015 [42] 2015 45–49 years age group females in a national-based survey 85 75.1
MoHP, 2015 [42] 2015 50–54 years age group females in a national-based survey 60 73.9
MoHP, 2015 [42] 2015 55–59 years age group females in a national-based survey 69 73.4
MoHP, 2015 [42] 2015 1–9 years age group males in a national-based survey 53 69.7
MoHP, 2015 [42] 2015 10–14 years age group males in a national-based survey 57 57.5
MoHP, 2015 [42] 2015 15–19 years age group males in a national-based survey 57 78.2
MoHP, 2015 [42] 2015 20–24 years age group males in a national-based survey 35 68.4
MoHP, 2015 [42] 2015 25–29 years age group males in a national-based survey 35 66.1
MoHP, 2015 [42] 2015 30–34 years age group males in a national-based survey 19 72.8
MoHP, 2015 [42] 2015 35–39 years age group males in a national-based survey 17 42.6
MoHP, 2015 [42] 2015 40–44 years age group males in a national-based survey 16 78.0
MoHP, 2015 [42] 2015 45–49 years age group males in a national-based survey 14 70.6
MoHP, 2015 [42] 2015 50–54 years age group males in a national-based survey 14 67.1
MoHP, 2015 [42] 2015 55–59 years age group males in a national-based survey 12 27.5
Jhaveri, 2015 [59] 2012–14 Pregnant women/ANC attendees 98 55.0
Kalil, 2010 [60] 2004–05 Children 121 72.0
Kassem, 2000 [61] 1996 Pregnant women/ANC attendees 19 73.7
Khamis, 2014 [62] - Pregnant women/ANC attendees 20 45.0
Kumar, 1997 [63] 1994–96 Pregnant women/ANC attendees 65 31.0
Nafeh, 2000 [64] - Participants in a population-based survey 514 63.0
Strickland, 2002 [65] - Healthy individuals 99 74.7
Tanaka,2004 [66] 1999 Blood donors 317 71.0
Zuure,2013 [67] 2009–10 General population 11 90.9
(Continued)
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Table 1. (Continued)
Country First author, year of publication Years of data collection Population description Number of HCV Ab positive individuals tested for RNA HCV viremic rate (%)
Iran Doosti, 2009 [68] 2003–04 Blood donors 76 62.0
Farshadpour, 2010 [69] 2007–08 Blood donors 55 81.8
Iraq Obied, 2014 [70] 2012–13 Blood donors 20 65.0
Tawfeeq, 2013 [71] 2011–12 Blood donors 45 68.9
Jordan Rashdan, 2008 [72] 2004–06 Blood donors 29 89.6
Morocco Baha, 2013 [73] 2005–11 General population 195 70.9
Benouda, 2009 [74] 2005–07 General population 158 39.2
Pakistan Aziz, 2011 [75] 2005–09 Pregnant women/ANC attendees 640 79.7
Donchuk, 2016 [76] 2015–16 Outpatient hospital attendees 1,107 89.0
Idrees, 2008 [77] 1999–07 General population 857 49.2
Idrees, 2008 [77] 1999–07 General population 141 50.4
Karim, 2016 [78] 2015 Blood donors 60 93.0
Khokhar, 2004 [79] 2001–02 Pregnant women/ANC attendees 18 72.0
Rauf, 2011 [80] 2009 Refugees 18 44.4
Rauf, 2011 [80] 2009 Refugees 34 50.0
Palestine Shemer-Avni, 1998 [81] - Blood donors 34 71.0
Shemer-Avni, 1998 [81] - Outpatient hospital attendees 11 64.0
Tunisia Mejri, 2005 [82] 1996 General population 72 82.0
Mejri, 2005 [82] 1996 General population 14 71.4
Populations at intermediate risk (n = 20)
Algeria Mouffok, 2013 [83] 2003–12 HIV infected patients 22 54.5
Egypt Abdelwahab, 2012 [84] 2008–10 Diabetic patients 140 72.1
Chehadeh, 2011 [85] - Diabetic patients 20 80.0
Farghaly, 2014 [86] - Spouses of index patients 18 40.0
El-Karaksy, 2010 [56] 2006–07 Health care workers 25 66.7
Hassane, 1998 [87] - Household contacts of index patients 24 50.0
Hassane, 1998[87] - Household contacts of index patients 21 59.1
Hassane, 1998[87] - Household contacts of index patients 11 9.1
Madwar, 1999 [88] - Prisoners 28 100
Munier, 2013 [89] 2008–10 Diabetic patients 43 77.2
Mohamed, 2013 [90] - Health care workers 79 51.2
Shalaby, 2010 [91] 2007 Barbers and barbers’ clients 77 73.0
Kuwait Chehadeh, 2011 [85] - Diabetic patients (Kuwaitis) 11 72.7
Chehadeh, 2011 [85] - Diabetic patients (Egyptians) 20 80.0
Lebanon Mahfoud, 2010 [92] 2007–08 Prisoners 12 50.0
Libya Elzouki, 2014 [93] 2008–09 Health care workers 12 33.3
Morocco Cacoub, 2000 [94] 1995–96 Inpatients and outpatients 60 75.0
Rebbani, 2013 [95] 2006–10 HIV infected patients 27 77.8
Pakistan Qureshi, 2007 [96] - Health care workers 21 76.0
Zuberi, 2009 [97] 2004–08 Inpatients 10 90.0
Populations at high risk of healthcare-related exposures (n = 51)
Egypt Abdelwahab, 2012 [98] - Hemophilia patients 40 47.5
Hussein, 2014 [99] 2007–08 Thalassemia patients 48 100
Omar, 2011 [100] - Thalassemia patients 75 74.3
Said, 2013 [101] - Thalassemia patients 47 100
Salama, 2015 [102] - Thalassemia patients 40 55.0
Iran Abdollahi, 2008 [103] 2003 Hemophilia patients 145 80.2
Alvai, 2005 [104] 2002 Thalassemia patients 13 84.6
Asguar, 2007 [105] - Hemophilia patients 21 80.9
Assarehzadegan, 2012 [106] 2008–09 Hemophilia patients 47 89.4
Azarkeivan, 2011 [107] 2008 Thalassemia patients 170 66.0
Broumand, 2002 [108] - Hemodialysis patients 105 48.6
Faranoush, 2006 [109] - Thalassemia patients 222 60.0
Ghane, 2012 [110] 2010 Thalassemia patients 36 77.8
Joukar, 2011 [111] 2009 Hemodialysis patients 61 50.8
Kalantari, 2011 [112] 2009 Thalassemia patients 50 62.0
Kalantari, 2011 [112] 2009 Hemophilia patients 495 70.1
Makhlough, 2008 [113] 2006 Hemodialysis patients 39 53.8
Mousavi, 2002 [114] - Thalassemia patients 22 77.3
Samimi-Rad, 2007 [115] 2004 Bleeding disorder patients 34 68.0
Samimi-Rad, 2008 [116] 2005 Hemodialysis patients 14 64.3
Ziaee, 2005 [117] 2000 Thalassemia patients 44 56.8
(Continued)
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Table 1. (Continued)
Country First author, year of publication Years of data collection Population description Number of HCV Ab positive individuals tested for RNA HCV viremic rate (%)
Iraq Al-Kubaisy, 2006 [118] 1998 Hemodialysis patients 50 76.0
Al-Kubaisy, 2006 [118] 1998 Thalassemia patients 20 70.0
Abdullah, 2012 [119] 2010 Hemophiliacs co-infected with HIV 92 26.1
Khaled, 2014 [120] 2012 Thalassemia patients 50 88.0
Shihab, 2014 [121] 2012–13 Hemodialysis patients 52 61.5
Jordan Al-Sweedan, 2011 [122] 2008 Thalassemia patients 40 50.0
Bdour, 2002 [123] - Hemodialysis patients 92 31.5
Lebanon Abdelnour, 1997 [124] - Thalassemia patients 17 65.0
Ramia, 2002 [125] 1999–00 Hemodialysis patients 55 34.5
Libya Elzouki, 1995 [126] - Hemodialysis patients 32 72.0
Morocco Benani, 1997 [127] - Hemodialysis patients 49 48.9
Doblali, 2014 [128] 2010–12 Hemodialysis patients 26 65.4
Foullous, 2015 [129] - Hemodialysis patients 194 54.1
Lioussfi, 2014 [130] 2009 Hemodialysis patients 43 69.8
Oman Al Naamani, 2015 [131] 1991–01 Thalassemia patients 65 51.0
Palestine El-Ottol, 2010 [132] 2007 Hemodialysis patients 44 84.1
Saudi Arabia Hussein, 1994 [133] 1993 Hemodialysis patients 27 70.4
Syria Abdulkarim, 1998 [134] - Multi-transfused patients 56 87.5
Yazaji, 2016 [135] 2012–13 Hemodialysis patients 18 22.2
Tunisia Ayed, 2003 [136] 2001 Hemodialysis patients 310 75.5
Ayed, 2003 [136] 2001 Hemodialysis patients 55 70.9
Ayed, 2003 [136] 2001 Hemodialysis patients 44 90.9
Ayed, 2003 [136] 2001 Hemodialysis patients 60 93.3
Ayed, 2003 [136] 2001 Hemodialysis patients 243 60.5
Ayed, 2003 [136] 2001 Hemodialysis patients 116 71.5
Ben Othman, 2004 [137] 2000–02 Hemodialysis patients 42 76.2
Ben Othman, 2004 [137] 2000–02 Hemodialysis patients 15 86.7
Ben Othman, 2004 [137] 2000–02 Hemodialysis patients 33 78.8
Hmaied, 2006 [138] 2001–03 Hemodialysis patients 79 73.0
Sassi, 2000 [139] - Hemodialysis patients 27 51.8
People who inject drugs (n = 5)
Afghanistan Nasir, 2011 [140] 2006–08 People who inject drugs 165 58.2
Nasir, 2011 [140] 2006–08 People who inject drugs 12 41.7
Nasir, 2011 [140] 2006–08 People who inject drugs 44 59.1
Iran Mansoori, 2003 [141] 1998–00 HIV patients with intravenous drug use as main mode of
exposure
15 80.0
Lebanon Mahfoud, 2010 [142] 2007–08 People who inject drugs 56 50.0
Populations with liver-related conditions (n = 4)
Algeria Bensalem, 2016 [143] 2012 Patients referred to a confirmatory laboratory test 3,204 66.2
Algeria, Morocco,
Tunisia
Bahri, 2011 [144] 2002–05 Hepatocellular carcinoma patients 98 93.0
Egypt Angelico, 1997 [145] 1993–95 Chronic liver disease patients 91 55.0
Quinti, 1997 [146] - Acute viral hepatitis patients 23 87.0
Strickland, 2002 [65] - Chronic liver disease patients 138 69.6
Iraq Al-Kubaisy, 2014 [147] 2000–03 Hepatocellular carcinoma patients 17 70.8
Morocco Tayeb, 2012 [148] - HCV Ab positive patients 46 43.5
Pakistan Sundus, 2013 [149] 2009–10 Hepatitis patients 151 98.0
Special clinical populations (n = 16)
Egypt Cowgill, 2004 [52] 1999–03 Non-Hodgkin’s lymphoma patients 106 89.0
El Garf, 2012 [150] 2009 Rheumatoid arthritis patients 21 71.4
Mahmoud, 2011 [151] 2009–10 Rheumatoid arthritis patients 22 63.6
Mostafa, 2003 [152] 2000–01 Cancer patients on chemotherapy 13 38.5
Mostafa, 2003 [152] 2000–01 Cancer patients on chemotherapy 44 47.7
Sabry, 2005 [153] - Glomerulonephritis patients 90 55.6
Sharaf-Eldeen, 2007 [154] - Lichen planus patients 43 76.8
Youssef, 2009 [155] - Patients with liver complaints 156 57.7
Pakistan Mahboob, 2003 [156] 1999–01 Lichen planus patients 16 62.5
Saudi Arabia Halawani, 2012 [157] 2007–09 Urticarial patients 12 75.0
Halawani, 2010 [158] - Lichen planus patients 24 62.5
Tunisia Lakhoua Gorgi, 2010 [159] 1987–04 Renal transplant patients 24 91.7
Mixed populations (n = 1)
Libya Saleh, 1994 [40] 1992 Blood donors, health care workers, and outpatients 18 66.7
Abbreviations: Ab = Antibody, ANC = Antenatal care, HCV = Hepatitis C virus, MoHP = Ministry of Health and Population, RNA = Ribonucleic acid.
https://doi.org/10.1371/journal.pone.0187177.t001
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(95% CI: 66.6–70.8%) for studies using probability-based sampling at the national level, and
68.2% (95% CI: 64.8–71.6%) in studies using convenience sampling.
There was (overall) evidence for strong heterogeneity in HCV viremic rate in all the differ-
ent meta-analyses with generally a p-value <0.0001 (Tables 2–4). The I2 for the pooled esti-
mates indicated that the vast majority of the variation was due to true variation in HCV
viremic rate across studies rather than chance (generally I2 >>50%). The prediction intervals
were generally very broad confirming substantial variation in measured HCV viremic rate
across studies. Forest plots for the meta-analyses by risk population can be found in S2 Fig.
Predictors of HCV viremic rate and sources of heterogeneity
Table 5 displays the results of the univariable meta-regressions to identify the predictors of
HCV viremic rate and sources of between-study heterogeneity. None of the hypothesized pre-
dictors were statistically significant (p-value >0.05), and none were eligible for inclusion in the
final multivariable model (p-value >0.1). Therefore, no multivariable meta-regression was
conducted.
Though no variables were significantly predictive of HCV viremic rate, there were notably
trends of lower viremic rate for females and children (Table 5), and trends of higher viremic
rate for populations with liver-related conditions and for populations with high (>50%) HCV
Ab prevalence.
Discussion
Through a comprehensive analysis of systematically extracted data, we investigated HCV vire-
mic rate in the MENA region. We found that about two-thirds of HCV Ab positive individuals
Table 2. Pooled mean estimate for hepatitis C virus (HCV) viremic rate by risk population in the Middle East and North Africa.
Population at risk Studies HCV Ab
prevalencea
HCV RNA positivity among HCV Ab positive individuals
Sample Prevalence Prevalence Heterogeneity measures
Total N Mean (95% CI) Total N Range (%) Mean (95%
CI)
Qb (p-value) I2c (95% CI) Prediction
intervald (%)
General populations 81 10.4 (8.4–12.5) 10,448 26–100 66.9 (62.6–
71.1)
1,510.9
(p < 0.0001)
94.7 (93.9–
95.3)
29.1–95.3
Populations at intermediate risk 20 10.4 (6.8–14.6) 682 9–100 67.1 (58.6–
75.2)
85.2
(p < 0.0001)
77.7 (66.0–
85.4)
30.9–94.9
Populations at high risk
healthcare-related exposures
51 31.3 (36.0–36.7) 3,814 22–100 68.5 (63.5–
73.3)
478.0
(p < 0.0001)
89.5 (87.1–
91.5)
33.7–94.8
People who inject drugs 5 42.2 (23.9–61.8) 292 50–80 57.4 (49.4–
65.2)
5.6 (p = 0.23) 28.8 (0.0–
72.3)
37.2–76.4
Populations with liver-related
conditions
8 6.5 (43.8–83.0) 3,768 43–98 75.5 (61.0–
87.6)
190.0
(p < 0.0001)
96.3 (94.5–
97.5)
22.3–100
Special clinical populations 12 30.1 (19.6–41.8) 571 38–91 67.4 (56.7–
77.3)
62.6
(p < 0.0001)
82.4 (70.6–
89.5)
28.7–96.2
All studiese 178 18.8 (16.7–21.1) 19,593 9–100 67.6 (64.9–
70.3)
2,351.7
(p < 0.0001)
92.5 (91.6–
93.2)
33.7–93.8
a This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.
b Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.
c I2: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
d Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.
e A study including a mixed population group [40] was also considered in the meta-analysis.
Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.
https://doi.org/10.1371/journal.pone.0187177.t002
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are chronically infected with HCV infection. Though the viremic rate varied widely across
studies, the pooled mean HCV viremic rate was similar regardless of risk population or sub-
population, country or subregion, HCV Ab prevalence, sex, or study sampling method. The
overall pooled mean viremic rate of 67.6% (95% CI: 64.9–70.3%) was also similar to that found
in large population-based and nationally-representative surveys such as those of the Demo-
graphic and Health Surveys in Egypt that reported a viremic rate of 66.6% (in 2008) [41] and
70.2% (in 2015) [42].
HCV viremic rate is defined as the proportion of chronically infected individuals (HCV Ab
positive and RNA positive), out of all ever infected individuals (HCV Ab positive regardless of
RNA status). Accordingly, it is closely linked to HCV clearance rate, defined as the proportion
of people who spontaneously clear their infection—that is the proportion of people who clear
their acute infection and do not become chronically infected [11]. Our results then imply that
over 30% of infected individuals spontaneously clear their infection, a higher proportion than
that estimated in prospective cohort studies of about 25% [7, 23]. While prospective studies
provide a direct approach to estimating the clearance rate, there are known methodological
limitations and potential biases that may lead to underestimation of clearance rate [7, 11, 22].
Our results, using an independent methodology from that of prospective studies, suggest that
one-third of infected individuals spontaneously clear their infection.
In planning for this study, our implied hypothesis was that we will identify several predic-
tors of higher HCV viremic rate. PWID and populations at high risk of healthcare-related
exposures may have a weaker immune system and are at a higher risk of HCV reinfection,
therefore should have a higher viremic rate. Female sex is associated with higher spontaneous
clearance rate [7, 23, 43], and therefore we expected the viremic rate among men to be larger
than that among women. We further expected a higher viremic rate in populations with higher
Table 3. Pooled mean estimate for hepatitis C virus (HCV) viremic rate by country or relevant subregion in the Middle East and North Africa.
Country or relevant
subregion
Studies HCV Ab
prevalencea
HCV RNA positivity among HCV Ab positive individuals
Sample Prevalence Prevalence Heterogeneity measures
Total N Mean (95% CI) Total N Range (%) Mean (95% CI) Q b (p-value) I2c (95% CI) Prediction intervald
(%)
Afghanistan/Pakistan 15 20 (13.1–27.9) 3,294 41–98 70.4 (57.4–
82.0)
628.9
(p < 0.0001)
97.8 (97.2–
98.3)
17.1–100
Egypt 89 16.9 (14.2–19.9) 8,348 9–100 67.0 (63.1–
70.8)
1,108.0
(p < 0.0001)
92.1 (90.8–
93.1)
31.5–94.4
Fertile Crescent 20 18.4 (13.2–24.2) 810 22–89 62.1 (50.0–
72.7)
182.9
(p < 0.0001)
89.6 (85.4–
92.6)
14.2–98.6
Gulf 6 20.5 (7.9–36.9) 159 51–80 65.9 (55.3–
75.9)
7.9 (p = 0.15) 37.2 (0.0–
75.0)
38.9–88.7
Iran 19 28.6 (16.1–43.0) 1,664 48–89 68.6 (63.2–
73.8)
74.3 (p < 0.0001) 75.8 (62.3–
84.4)
46.8–86.9
Maghreb 29 18.2 (13.9–22.9) 5,318 33–93 70.4 (65.5–
75.1)
222.7
(p < 0.0001)
87.4 (83.1–
90.7)
45.0–90.7
All countries 178 18.8 (16.7–21.1) 19,593 9–100 67.6 (64.9–
70.3)
2,351.7
(p < 0.0001)
92.5 (91.6–
93.2)
33.7–93.8
a This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.
b Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.
c I2: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
d Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.
Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.
https://doi.org/10.1371/journal.pone.0187177.t003
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HCV Ab prevalence, as HCV Ab prevalence can be seen as a proxy for the risk of repeated
HCV exposures. Lastly, we expected a higher viremic rate in populations with liver-related
conditions, since the presence of these conditions could be indicative of chronic HCV
infection.
Nevertheless, none of these hypothesized effects were identified as statistically significant in
our meta-regression analyses. Though there was a trend of lower viremic rate in women-only
studies, and trends of higher viremic rate in populations with liver-related conditions and pop-
ulations with higher (>50%) HCV Ab prevalence, none of these trends reached statistical sig-
nificance. These results suggest that either some of these effects may not be present as
originally hypothesized, or that the effect size of these effects was not large enough to be
Table 4. Pooled mean estimate for hepatitis C virus (HCV) viremic rate by risk subpopulation, sex, and sampling method in the Middle East and
North Africa.
Variables Studies HCV Ab
prevalencea
HCV RNA positivity among HCV Ab positive individuals
Sample Prevalence Effect size Heterogeneity measures
Total N Mean (95% CI) Total N Range (%) Mean (95%
CI)
Qb (p-value) I2c (95% CI) Prediction
intervald (%)
Subpopulations among the general population
Blood donors 8 1.4 (0.5–2.7) 636 62–93 76.3 (68.6–
84.0)
30.94
(p < 0.0001)
77.4 (55.2–
88.6)
46.5–95.6
Children 7 3.7 (1.1–7.6) 225 27–75 54.0 (37.6–
70.0)
26.1
(p < 0.0002)
77.0 (51.9–
89.0)
7.6–96.4
Pregnant women/ANC attendees 9 7.7 (5.8–9.9) 1,084 26–79 58.1 (42.1–
73.4)
149.3
(p < 0.0001)
94.6 (91.8–
96.5)
7.4–99.2
Other general populations 57 13.9 (10.8–17.1) 8503 29–100 68.1 (62.9–
73.1)
1,290.8
(p < 0.0001)
95.7 (94.9–
96.3)
28.8–96.6
Subpopulations among the populations at high risk healthcare-related exposures
Hemophilia patients 6 55.7 (35.6–74.9) 782 48–89 73.6 (63.9–
82.3)
25.7
(p < 0.0001)
80.5 (58.0–
91.0)
40.0–96.6
Hemodialysis patients 27 26.3 (22.0–30.1) 1,967 26–93 66.5 (59.5–
73.2)
241.6
(p < 0.0001)
89.2 (85.6–
92.0)
30.4–94.4
Thalassemia patients 16 29.6 (22.2–37.5) 1,027 34–100 72.1 (61.6–
81.6)
177.5
(p < 0.0001)
91.5 (87.9–
94.1)
26.3–99.9
Sex
Females 33 11.0 (8.4–13.9) 2,712 26–100 65.4 (60.1–
70.6)
225.5
(p < 0.0001)
85.8 (81.1–
89.4)
36.3–89.6
Males 26 15.1 (10.4–20.5) 2,953 27–100 67.4 (58.1–
76.0)
582.5
(p < 0.0001)
95.7 (94.6–
96.6)
20.0–99.4
Mixed 119 22.5 (19.4–25.7) 13,928 9–100 68.2 (64.9–
71.3)
1,542.1
(p < 0.0001)
92.3 (91.3–
93.2)
34.9–93.9
Sampling methods
Convenience sampling 126 22.4 (19.4–25.5) 13,713 9–100 68.2 (64.8–
71.6)
1,843.8
(p < 0.0001)
93.2 (92.4–
94.0)
31.5–95.6
National population-based and
probability-based sampling
41 11.2 (7.9–14.9) 3,112 28–82 68.7 (66.6–
70.8)
57.92
(p < 0.0003)
30.9 (0.0–
53.1)
60.7–76.1
Other probability-based sampling 11 13.9 (5.9–24.5) 2,768 29–76 58.7 (49.4–
67.6)
170.4
(p < 0.0001)
94.1 (91.3–
96.0)
25.8–87.8
a This mean is the mean of HCV Ab prevalence in the study population from which the HCV viremic rate was extracted.
b Q: The Cochran’s Q statistic is a measure assessing the existence of heterogeneity in effect size.
c I2: A measure that assesses the magnitude of between-study variation that is due to differences in effect size across studies rather than chance.
d Prediction interval: A measure that estimates the 95% interval in which the true effect size in a new study will lie.
Abbreviations: Ab = Antibody, ANC = Antenatal care, CI = Confidence interval, HCV = Hepatitis C virus, RNA = Ribonucleic acid.
https://doi.org/10.1371/journal.pone.0187177.t004
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detected in our sample of 178 viremic rate measures, or that the heterogeneity in the effect size
lowered the power of the analysis to detect these differences.
Though we could not identify any significant predictor of HCV viremic rate, the viremic
rate varied widely across studies. This may suggest that much of this variation could be due to
random effects, such as those related to the complex laboratory methods used in assessing the
viremic rate. Assessment of HCV viremic rate requires a two-test algorithm, for HCV Ab and
HCV RNA, and the diagnostic assays and protocols can vary from one study to another. Dif-
ferent assays, whether for HCV Ab or for HCV RNA, may also have different sensitivities and
specificities, which can impact the estimated HCV viremic rate [44, 45]. Even small random
errors in assessing the denominator (HCV Ab positive cases), or the numerator (HCV RNA
positive cases), can lead to large variation in calculated viremic rate.
Another source of random errors in calculated HCV viremic rate could be sampling varia-
tion as the “effective” sample size in viremic rate studies (the number of HCV Ab positive
Table 5. Univariable meta-regression models for hepatitis C virus (HCV) viremic rate in the Middle East and North Africa.
Number of studies Univariable analysis
OR (95% CI) p-value
Risk population General populations 81 1 -
Populations at intermediate risk 20 0.9 (0.6–1.6) 0.887
Populations of high risk healthcare-related exposures 51 1.1 (0.8–1.5) 0.483
PWID 5 0.6 (0.3–1.7) 0.375
Populations with liver-related conditions 8 1.7 (0.8–3.6) 0.147
Special clinical populations 12 1.0 (0.5–1.8) 0.97
Region Egypt 89 1 -
Afghanistan/Pakistan 15 1.2 (0.7–2.1) 0.541
Fertile Crescenta 20 0.8 (0.5–1.3) 0.309
Gulfb 6 1.0 (0.4–2.3) 0.971
Iran 19 1.1 (0.6–1.8) 0.793
Maghrebc 29 1.1 (0.7–1.7) 0.566
Sex Females 33 1 -
Males 26 1.1 (0.7–1.9) 0.66
Mixed 119 1.1 (0.7–1.6) 0.559
Age Children 14 1 -
Adults 164 1.5 (0.9–2.6) 0.139
Prevalence of HCV Ab positive 1–10% 56 1 -
10–30% 69 1.2 (0.8–1.7) 0.331
30–50% 32 1.1 (0.7–1.8) 0.637
>50% 16 1.6 (0.9–2.8) 0.113
Year of data collection Before 2000 42 1 -
2000 and thereafter 136 1.2 (0.9–1.7) 0.217
Sample size <50 89 1 -
50 89 1.0 (0.7–1.4) 0.75
Sampling methods Non-probability based sampling 126 1 -
Probability based sampling 50 0.8 (0.6–1.2) 0.272
a Fertile Crescent includes: Iraq, Jordan, Lebanon, Palestine, and Syria.
b Gulf includes: Kuwait, Oman, and Saudi Arabia.
c Maghreb includes: Algeria, Libya, Morocco, and Tunisia.
Abbreviations: Ab = Antibody, CI = Confidence interval, HCV = Hepatitis C virus, PWID = People who inject drugs, OR = Odds ratio.
https://doi.org/10.1371/journal.pone.0187177.t005
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cases), tend to be small (Table 1). The number of HCV Ab positive cases is most often a sub-
sample of the original study sample size—the original study sample size is the number of indi-
viduals recruited in the original study whose serostatus could be HCV Ab negative or HCV Ab
positive. The median size of the (sub) sample of HCV Ab positive cases in included studies was
only 50. With a viremic rate of 67.6% (as was the pooled estimate), this small median sample
size leads to a wide confidence interval (95% CI: 53.3%-80.5%). This highlights how (sub) sam-
ple size could be a major cause of the observed variation.
The large variations in HCV viremic rate across studies (Table 1), but the small variations
in the pooled mean HCV viremic rates (Tables 2–4), suggest caution against using the highly
variable and possibly error-prone study-specific viremic rates in estimations of the number of
HCV chronic carriers in different populations and countries, instead of the stable pooled
means. We advocate here for the use of one standardized HCV viremic rate, say the overall
pooled mean estimated in this study (Table 2), in ongoing chronic HCV infection estimations
—such as the global estimations being conducted for the World Health Organization [3]. We
further advocate for the use of pooled means, rather than study-specific estimates, for assessing
and monitoring the progress in (and coverage of) HCV treatment programs, as we forge ahead
towards HCV elimination by 2030. Of notice here that this progress monitoring will require
repeated population-based measures of HCV antibody positivity and HCV RNA positivity in
the same population, with sufficiently large sample sizes to assess statistically the trends in
HCV viremic rate.
Our study has several limitations. The availability of data varied by risk population and
country, and we did not identify any HCV viremic rate data for eight MENA countries. The
number of studies was limited for some risk populations—only five studies were identified for
PWID, and these were mostly conducted among PWID with access to prevention programs.
Sample size varied across studies, and the sampled risk population may not have been repre-
sentative of the wider risk population in the country. Despite these limitations, we identified a
substantial volume of viremic rate data in MENA that facilitated the conduct of different types
of analyses, thereby generating informative inferences.
Conclusions
Two-thirds of HCV Ab positive individuals in MENA are chronically infected with HCV
infection, implying that over 30% of infected individuals spontaneously clear their infection.
Though there was extensive variation in the study-specific HCV viremic rates, the pooled
mean viremic rates were similar regardless of risk population or subpopulation, country or
subregion, HCV Ab prevalence in the background population, or sex. These findings argue for
the use of one standardized HCV viremic rate, such as the overall pooled mean viremic rate
provided in this study, in estimations of the number of HCV chronic carriers in different pop-
ulations and countries. These findings also highlight the utility of using the pooled mean vire-
mic rate as an indicator to track the progress in (and coverage of) HCV treatment programs in
different risk populations and countries, as viral hepatitis treatment programs are established
and/or expanded with the ultimate target of HCV elimination by 2030.
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